Rheumatology International

, Volume 32, Issue 4, pp 991–995 | Cite as

The status of serum vitamin D in patients with rheumatoid arthritis and undifferentiated inflammatory arthritis compared with controls

  • Behzad Heidari
  • Karimollah Hajian-Tilaki
  • Parnaz Heidari
Original Article


Inadequate vitamin D may be involved in the pathogenesis and or progression of several disorders, including connective tissue diseases. To determine the status of vitamin D in different stages of inflammatory arthritis, the levels of vitamin D in established rheumatoid arthritis (RA) and undifferentiated inflammatory arthritis (UIA) were compared with controls. Patients with RA and UIA entered the study. Serum 25-hydroxyvitamin D (25-OHD) was measured by ELISA method, and concentrations less than 20 ng/ml were considered as deficient levels. In statistical analysis, the Mann–Whitney U test was used for comparing differences between groups and logistic regression analysis with calculation of adjusted odds ratio (OR) was used to determine the association between serum 25-OHD deficiency and disease condition. A total of 108 RA, 39 UIA, and 239 controls were studied. There were no significant differences in mean serum 25-OHD level and frequency of serum 25-OHD deficiency between RA and controls (37 ± 37.7 vs. 33.2 ± 28.6 ng/ml, P = 0.96). But the mean serum 25-OHD level in UIA was significantly lower than in the controls (25.1 ± 23.9 vs. 33.2 ± 28.6 ng ml, P = 0.04). A significant positive association was observed between serum 25-OHD deficiency and UIA (56.4% vs. 35.5%, OR = 2.34, 95% CI, 1.18–4.65, P = 0.021) which remained significant after adjustment for sex and age (adjusted OR = 2.24, 95% CI, 1.01–4.55, P = 0.026). Whereas the association between serum 25-OHD deficiency and RA did not reach statistical significance (40.7% vs. 35.5%, OR = 1.24, 95% CI, 0.78–1.99). These findings indicate higher serum vitamin D deficiency in patients with ongoing arthritis rather than established arthritis. Respecting to deleterious effects of vitamin D deficiency on immune system and progressive nature of UIA, a significant proportion of high risk UIA can be recognized by serum 25-OHD determination.


Vitamin D deficiency Rheumatoid arthritis Undifferentiated inflammatory arthritis Association 


  1. 1.
    Holick MF (2006) High prevalence of vitamin D inadequacy and implications for health. Mayo Clin Proc 81:353–373PubMedCrossRefGoogle Scholar
  2. 2.
    Gannagé-Yared MH, Tohmé A, Halaby G (2001) Hypovitaminosis D: a major worldwide public health problem. Presse Med 7(30):653–658Google Scholar
  3. 3.
    Adams JS, Hewison M (2010) Update in vitamin D. J Clin Endocrinol Metab 95:471–478PubMedCrossRefGoogle Scholar
  4. 4.
    Cutulo M, Otsa K, Paolino S, Yrrus M, Veldi T, Seriolo B (2008) Vitamin D involvement in rheumatoid arthritis and systemic lupus erythgmatosus. Ann Rheum Dis 67:530–535Google Scholar
  5. 5.
    Pérez-López FR (2007) Vitamin D and its implications for musculoskeletal health in women: an update. Maturitas 58(2):117–137 (Epub 2007 Jun 29)PubMedCrossRefGoogle Scholar
  6. 6.
    Arnson Y, Amital H, Shoenfeld Y (2007) Vitamin D and autoimmunity: new etiological and therapeutic considerations. Ann Rheum Dis 66:1137–1142PubMedCrossRefGoogle Scholar
  7. 7.
    Ranganathan P (2009) Genetics of bone loss in rheumatoid arthritis—role of vitamin D receptor polymorphisms. Rheumatology (Oxford) 48(4):342–346CrossRefGoogle Scholar
  8. 8.
    Tetlove LC, Wolley DE (1999) The effect of 1 alpha 25-dihydroxyvitamin D3 on matrixmetalloproteinase and prostgalndin E2 production by cells of rheumatoid lesion. Arthritis Res 1:63–70CrossRefGoogle Scholar
  9. 9.
    Albert PJ, Proal AD, Marshall TG (2009) Vitamin D: the alternative hypothesis. Autoimmun Rev 8(8):639–644PubMedCrossRefGoogle Scholar
  10. 10.
    Szodoray P, Nakken B, Gaal J et al (2008) The complex role of vitamin D in autoimmune diseases. Scand J Immunol 68(3):261–269PubMedCrossRefGoogle Scholar
  11. 11.
    Deluca HF, Cantorna MT (2001) Vitamin D: it’s role and uses in immunology. FASEB J 15:2579–2585PubMedCrossRefGoogle Scholar
  12. 12.
    Kamen DL, Aranow C (2008) The link between vitamin D deficiency and systemic lupus erythematosus. Curr Rheumatol Rep 10:273–280PubMedCrossRefGoogle Scholar
  13. 13.
    Alele JD, Kamen DL (2010) The importance of inflammation and vitamin D status in SLE-associated osteoporosis. Autoimmun Rev 9(3):137–139PubMedCrossRefGoogle Scholar
  14. 14.
    Cutolo M, Otsa K (2008) Review: vitamin D, immunity and lupus. Lupus 17(1):6–10PubMedCrossRefGoogle Scholar
  15. 15.
    Zold E, Szodoray P, Kappelmayer J et al (2008) Vitamin D deficiency in undifferentiated connective tissue disease. Arthritis Res Ther 10:R123PubMedCrossRefGoogle Scholar
  16. 16.
    Damanhouri LH (2009) Vitamin D deficiency in Saudi patients with systemic lupus erythematosus. Saudi Med J 30:1291–1295PubMedGoogle Scholar
  17. 17.
    Turhanoğlu AD, Güler H, Yönden Z, Aslan F, Mansuroglu A, Ozer C (2010) The relationship between vitamin D and disease activity and functional health status in rheumatoid arthritis. Rheumatol Int. doi:10.1007/s00296-010-1393-6
  18. 18.
    Craig SM, Yu F, Curtis JR et al (2010) Vitamin D status and its associations with disease activity and severity in African Americans with recent-onset rheumatoid arthritis. Rheumatol 37(2):275–281CrossRefGoogle Scholar
  19. 19.
    Braun-Moscovici Y, Toledano K, Markovits D, Rozin A, Nahir AM, Balbir-Gurman A (2009) Vitamin D level: is it related to disease activity in inflammatory joint disease? Rheumatol Int. doi:10.1007/s00296-009-1251-6
  20. 20.
    Patel S, Farrager T, Berry J, Bunn D, Silman A, Symmons D (2007) Association between serum vitamin D metabolites levels and disease activity in patients with early inflammatory polyarthritis. Arthritis Rheum 56:2143–2149PubMedCrossRefGoogle Scholar
  21. 21.
    Arnett FC, Edworthy SN, Bloch DA et al (1988) The American rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315–324PubMedCrossRefGoogle Scholar
  22. 22.
    Gottenberg JE, Miceli-Richard C, Ducot B, Goupille P, Combe B, Mariette X (2009) Markers of B—lymphocyte activation are elevated in patients with early rheumatoid arthritis and correlated with disease activity in the ESPOIR cohort. Arthritis Res Ther 11:R114PubMedCrossRefGoogle Scholar
  23. 23.
    Heidari B, Firouzjahi A, Heidari P, Hajian K (2009) The prevalence and diagnostic performance of anti-cyclic citrullinated peptide antibody in rheumatoid arthritis: the predictive and discriminative ability of serum antibody level in recognizing rheumatoid arthritis. Ann Saudi Med 29(6):467–470PubMedCrossRefGoogle Scholar
  24. 24.
    Szodoray P, Szabo Z, Kapitany A et al (2010) Anti-citrullinated protein/peptide autoantibodies in association with genetic and environmental factors as indicators of disease outcome in rheumatoid arthritis. Autoimmune Rev 9:140–143CrossRefGoogle Scholar
  25. 25.
    Caro-Oleas JL, Fernandez-Suarez A, Reneses CS, Porrino C, Nunez-Roldan A, Wichman SI (2008) Evaluation of third generation anti-CCP antibodies in the diagnosis of rheumatoid arthritis from undifferentiated polyarthritis after 4 years of follow—up. Clin Exp Rheumatol 26:461–463PubMedGoogle Scholar
  26. 26.
    Vaz CC, Couto M, Medeiros D et al (2009) Undifferentiated connective tissue disease: a seven—center cross-sectional a study of 184 patients. Clin Rheumatol 28:915–921PubMedCrossRefGoogle Scholar
  27. 27.
    Kudo-Tanaka E, Ohshima S, Ishi M (2007) Autoantibodies to cyclic citrullinated peptide 2 (CCP2) are superior to other potential diagnostic biomarkers for predicting rheumatoid arthritis in early undifferentiated arthritis. Clin Rheumatol 26:1627–1633PubMedCrossRefGoogle Scholar
  28. 28.
    Emery P, Durez P, Dougados M et al (2010) Impact of T cell costimulation modulation in patients with undifferentiated inflammatory arthritis or very early rheumatoid arthritis: a clinical and imaging study of abatacept (the ADJUST trial). Ann Rheum Dis 69:510–516PubMedCrossRefGoogle Scholar
  29. 29.
    Jeffery LE, Burke F, Mura M et al (2009) 1, 25-Dihydroxyvitamin D3 and IL-2 combine to inhibit T cell production of inflammatory cytokines and promote development of regulatory T cells expressing CTLA-4 and Fox3. J Immunol 183:5458–5467PubMedCrossRefGoogle Scholar
  30. 30.
    Cutolo M (2009) Vitamin D and autoimmune rheumatic disease. Rheumatology 48:210–212PubMedCrossRefGoogle Scholar
  31. 31.
    Andjelkovic Z, Voojinivic J, Pejnovic N et al (1999) Disease modifying and immunomodulatory effects of high dose 1 alpha (OH) D3 in rheumatoid arthritis patients. Clin Exp Rheumatol 17:453–456PubMedGoogle Scholar
  32. 32.
    Ruiz-Irastorza G, Gordo S, Olivares N, Egurbide MV, Aguirre C. (2010) Changes in vitamin D levels in patients with systemic lupus erythematosus: Effects on fatigue, disease activity an damage. Arthritis Care Res (Hoboken) [Epub ahead of print]. doi:10.1002/acr.20186
  33. 33.
    Gaal J, Lakos G, Szodoray P et al (2009) Immunological and clinical effects of alphacalcidiol in patients with psoriatic arthropathy: results of an open, follow-up pilot study. Acta Derm Venerol 89:140–144PubMedGoogle Scholar
  34. 34.
    Gouch A, Sambrook P, Delvin J et al (1998) Effect of vitamin D receptor gene alleles on bone loss in early rheumatoid arthritis. J Rheumatol 25:864–868Google Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • Behzad Heidari
    • 1
  • Karimollah Hajian-Tilaki
    • 2
  • Parnaz Heidari
    • 3
  1. 1.Department of Internal Medicine, Division of Rheumatology, Rouhani HospitalBabol University of Medical ScienceBabolIran
  2. 2.Department of Social MedicineBabol University of Medical SciencesBabolIran
  3. 3.Faculti of MedicineTehran Azad University of Medical SciencesTehranIran

Personalised recommendations